United StatesBreaking News

Korn Ferry (NYSE:KFY) reported fourth quarter FY'26 fee revenue of $759.8 million, a 7% increase from the prior year.

Applied Industrial Technologies (NYSE:AIT) announced a quarterly cash dividend of $0.51 per common share to reward its equity investors.

Teleflex Incorporated (NYSE:TFX) announced the beginning of enrollment in the BIOMAG-III Study, a global pivotal trial evaluating the Freesolve Resorbable Magnesium Scaffold (RMS).

Jiayin Group (NASDAQ:JFIN) reported first quarter 2026 unaudited results with transaction volume of RMB19.3 billion, a 45.8% decrease from the prior year.

Dorian LPG (NYSE:LPG) entered into an agreement with HD Hyundai to construct one 90,000 cbm very large gas carrier for delivery in July 2029 at a price of approximately $115 million.

SoftBank founder Masayoshi Son predicted that the AI race will be clinched by computing resources on Earth as he said there's little merit to building data centers in space, as championed by Elon Musk. Neil Campling reports on Bloomberg Television.

AEVEX (NYSE:AVEX) has been awarded the next option year of the Fire Integrated Real-Time Intelligence System (FIRIS) contract by the California Governor’s Office of Emergency Services (Cal OES), valued at $15.2 million.

Oracle Corp. reduced its workforce by a wider scale than previously known, cutting 21,000 employees in the past 12 months. The reductions include jobs that were eliminated by the use of artificial intelligence. Neil Campling reports on Bloomberg Television.

Organon (NYSE:OGN) and Shanghai Henlius Biotech, made BILDYOS (denosumab injection) 60 mg/1 mL and TUZEMTY (denosumab injection) 120 mg/1.7 mL available in Canada.

Less than two weeks after the year's most hotly anticipated IPO, investors are questioning the remaining upside of a company that seeks to raise billions in investor-grade debt as the AI trade stalls and other major offerings from OpenAI and Anthropic loom. Bloomberg's Charlie Wells discusses on "The Pulse with Francine Lacqua."

AbbVie (NYSE:ABBV) said the European Commission has granted approval for its oral antiviral MAVIRET (glecaprevir/pibrentasvir) to treat acute hepatitis C virus (HCV) infection in adults and pediatric patients aged 3 years and older with compensated liver disease, with or without cirrhosis.

Ludovic Subran, chief investment officer and chief economist at Allianz, discusses the outlook for technology stocks, inflation and central bank policy. He speaks on Bloomberg Television.